

ENABLING THE NEXT GENERATION OF NOVEL INSECTICIDES

BIO-GENE TECHNOLOGY LIMITED

18 NOVEMBER 2022

Annual General Meeting

PRESENTED BY

Robert Klupacs


NON-EXECUTIVE CHAIRMAN

Richard Jagger

CEO



BIO-GENE
TECHNOLOGY
LTD



DISCLAIMER

This presentation has been prepared by Bio-Gene Technology Limited (ASX:BGT) (the Company). This presentation is not, and should not be considered, an offer or invitation to apply for or purchase securities in the Company or as a recommendation or inducement to make an offer or invitation in respect of securities in the Company. No agreement to subscribe for securities will be entered into on the basis of this presentation or any information contained in this presentation.

This presentation is not a prospectus, product disclosure document or other offering document under Australian law or under the law of another jurisdiction. This presentation is provided for general information purposes only and is selective, does not purport to contain all relevant information and has not been independently verified.

Neither the Company nor its advisors have any responsibility or obligation to inform any recipient of any matter arising or coming to their notice after the date of this presentation, which may affect any matter referred to in the presentation. The Company releases material information as announcements to the ASX (ASX:BGT). Recipients seeking further information in respect of the Company should review the Company's announcements as released to ASX from time to time.

Nothing in this presentation constitutes investment, legal, tax, accounting or other advice. The recipient should consider its own financial situation, objectives and needs and conduct its own independent investigation and assessment, including obtaining investment, legal, tax, accounting or other advice as it considers necessary or appropriate.

The distribution of this presentation (including electronic copies) outside Australia may be restricted by law and persons who come into possession of this presentation outside Australia should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws.

This presentation may contain statements relating to intentions, future acts and events (Forward Looking Statements). Forward Looking Statements involve subjective judgment and analysis, known and unknown risks, uncertainties and other important factors that cause those future acts, events and circumstances to differ from the way or manner in which they are expressly or impliedly portrayed. No representation, warranty or guarantee, express or implied, is given that any Forward Looking Statements will be achieved or proven correct, or that any assumptions or projections on which the Forward Looking Statements are based are reasonable.

No financial information (unless also contained in financial reports released to ASX), estimates or projections contained in this presentation or as derived from such financial information, estimates or projections can be relied upon as a promise or representation as to any present or future matter.

To the maximum extent permitted by law, neither the Company nor any of its associates, directors, officers, employees, advisors or representatives make any representation or provide any warranty, express or implied, as to the accuracy, reliability or completeness of the information contained in this presentation or any subsequent information provided to the recipient including, but not limited to, any financial projections, estimates or other historical information.

OUR STRATEGIC OBJECTIVE

Generate multiple revenue streams from technology licensing fees, milestone payments and royalties by



Securing & owning active ingredient product registrations



Working with strong commercial partners on product development; marketing and distribution




Developing proprietary manufacturing and production know-how



Potential partnership agreements across multiple geographies and different end-use markets, with collaboration programs now underway in two of our target segments

IMPORTANT POSITIVE PROGRESS OVER THE PAST 12 MONTHS



Nov 2021 to Nov2022



PUBLIC HEALTH: COMMERCIAL AGREEMENT SIGNED ON CLARKE MOSQUITO PROJECT

Clarke is the largest vertically integrated company in public health mosquito control

Results of Phase 2 Testing

Very positive results indicate the suitability of Bio-Gene products as mosquito control technology

Target formulations identified for progression to Phase 3 field trials

Confidence for both companies to move forward with commercial negotiations as per the Option agreement

Commercial Development Agreement Signed

Development of novel formulations

Phase 3 field testing

Agreement is for the U.S. market

Cost of studies borne by Clarke, with shared report of results

Next Steps

Clarke undertaking Phase 3 trials (somewhat weather dependent) using new formulations

Field studies designed to confirm suitability of laboratory developed formulations for field use & EPA registration

Market Opportunity

Initial Field of Use: US\$100m¹

Global market \$650m¹



¹ Global Mosquito Control Market, Research Report 2020, Forecast to 2026

CONSUMER PRODUCTS: EVERGREEN COMMERCIAL DEVELOPMENT AGREEMENT

Evergreen is a market leader in consumer products across Europe and in Australia/New Zealand

Initial Field of Use

Fly & mosquito electric evaporator
Ant bait gel and ant spray

ROFR to negotiate additional applications within consumer market

Initial Territory

E.U., U.K., A/NZ
ROFR to negotiate additional territories within consumer market

Revenue Model

Up-front licence fee
Milestone payments prior to registration
On-going royalties on end-use product sales
Development costs borne by Evergreen

Market Opportunity

Initial Field of Use:
US\$600m¹

Total European consumer insecticide market: US\$2b¹



CROP PROTECTION: UPDATE ON STORED GRAIN PROJECT

Grains Research and Development Corporation (GRDC) Department of Agriculture and Fisheries - Queensland (DAF)

Results of Phase 3 testing

Data show the ability for Flavocide, when used in combination (at low rates) to control the full range of stored grain pests over 9 months for susceptible strains and 3-9 months for resistant strains (commercially acceptable time frame).

Further Discussions

Bio-Gene is discussing next steps with potential partners to progress the commercial development of Flavocide as a stored grain protectant

Next we will discuss support from the GRDC



Field testing completed
Nov/Dec 2021

Final reporting on these
results March 2022

Positive outcome allows
us to move forward

**Market opportunity in
Australia is relatively
small, but there is
significant global
potential (A\$1b)¹**

IMPORTANT PROGRESS – COMMERCIAL

Other commercial discussions

- Recent visit to Europe
Meetings with existing and new companies for product evaluation & commercial discussions
 - Valuable to have the opportunity to conduct face to face meetings and develop relationships.
 - Opportunities exist for further commercial development over the coming months as well as new relationships into 2023
-

Additional MTAs

- On-going process of adding new companies under MTAs to undertake formal testing program. Additional MTAs signed after recent Europe visit
 - Studies performed by these companies ultimately give Bio-Gene additional options for going to market
-

Efficacy testing

- Additional studies underway for specific evaluation of technology
 - Animal Health
 - Consumer
 - Crop Protection
 - Public Health
 - Extension work to identify additional key targets and applications to support our commercial discussions and further develop our I.P. portfolio
-

Continuing to develop our commercial relationships will ultimately provide further market access & revenue opportunities for Bio-Gene

IMPORTANT PROGRESS ACROSS OTHER KEY AREAS

Patents

- Patent allowance in the United States
- 1 additional recently submitted in Australia (Qcide)
- Applications under review in other key markets
- Other data collated for new submissions

Other I.P. Developments

- Recent research completed has the potential to identify new I.P. (patent) for the company
- Work on Qcide tree phenotypes has enabled commencement of Plant Breeders Rights program
- I.P. can be in the form of patents, technical & manufacturing knowhow, trade secrets

Review Of Registration Requirements

- Completed a regulatory review analysis with global consultants to look at the specific data requirements for USA, European Union and Australia across our different market segments
- Clear understanding developed relating to read-across potential for different applications and regulatory jurisdictions.
- Contact with regulatory agencies in key target jurisdictions with our commercial partners
- Submission made with EPA in the United States for a Biochemical classification of Flavocide.

Manufacturing

- Flavocide manufacturing validation – scale-up process has confirmed ability to produce larger quantities - 100Kg then 1,000kg
- Projects to further improve the economics of production of Flavocide are continuing
- Last Qcide harvest confirmed production improvements based on modified temperature & pressure
- Commercial plant tissue culture service provider has been initiated to establish the superior tree lines

On-going research is focused on developing data to support key commercial discussions as well as enhancing our I.P. portfolio

KEY PRIORITIES FOR THE NEXT 12 MONTHS

Broadening our future opportunities via new partnerships


Progressing development work associated with existing partnerships

Building our data to support efficacy, novel Mode of Action, and strengthen our IP


Optimising our manufacturing and production processes, scaling up production

Advancing our regulatory data and progress with governing bodies

Advancing the terms of our partnerships



A CLEAR ROAD MAP FOR GENERATING VALUE – MEDIUM TERM



ENABLING THE NEXT GENERATION OF NOVEL INSECTICIDES

BIO-GENE TECHNOLOGY LIMITED

18 NOVEMBER 2022

Annual General Meeting

THANK YOU



BIO-GENE
TECHNOLOGY
LTD